BR112016018455A2 - composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto. - Google Patents
composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto.Info
- Publication number
- BR112016018455A2 BR112016018455A2 BR112016018455A BR112016018455A BR112016018455A2 BR 112016018455 A2 BR112016018455 A2 BR 112016018455A2 BR 112016018455 A BR112016018455 A BR 112016018455A BR 112016018455 A BR112016018455 A BR 112016018455A BR 112016018455 A2 BR112016018455 A2 BR 112016018455A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- enteropeptidase
- medication
- inhibit
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014025832 | 2014-02-13 | ||
JP2014-025832 | 2014-02-13 | ||
PCT/JP2015/000639 WO2015122187A1 (en) | 2014-02-13 | 2015-02-12 | Fused heterocyclic compound |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016018455A2 true BR112016018455A2 (pt) | 2018-05-08 |
BR112016018455B1 BR112016018455B1 (pt) | 2022-09-06 |
Family
ID=52589729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016018455-6A BR112016018455B1 (pt) | 2014-02-13 | 2015-02-12 | Composto, medicamento, e, uso de um composto |
Country Status (39)
Country | Link |
---|---|
US (2) | US9346776B2 (pt) |
EP (1) | EP3105213B1 (pt) |
JP (2) | JP6383427B2 (pt) |
KR (1) | KR102378454B1 (pt) |
CN (1) | CN105980370B (pt) |
AR (1) | AR099400A1 (pt) |
AU (1) | AU2015216438B2 (pt) |
BR (1) | BR112016018455B1 (pt) |
CA (1) | CA2938191C (pt) |
CL (1) | CL2016001911A1 (pt) |
CR (1) | CR20160367A (pt) |
CY (1) | CY1121534T1 (pt) |
DK (1) | DK3105213T3 (pt) |
DO (1) | DOP2016000206A (pt) |
EA (1) | EA032201B1 (pt) |
EC (1) | ECSP16067137A (pt) |
ES (1) | ES2717113T3 (pt) |
HR (1) | HRP20190369T1 (pt) |
HU (1) | HUE042709T2 (pt) |
IL (1) | IL246838B (pt) |
JO (1) | JO3472B1 (pt) |
LT (1) | LT3105213T (pt) |
MA (1) | MA39246A1 (pt) |
ME (1) | ME03422B (pt) |
MX (1) | MX368392B (pt) |
MY (1) | MY173607A (pt) |
NZ (1) | NZ722035A (pt) |
PE (1) | PE20161243A1 (pt) |
PH (1) | PH12016501582A1 (pt) |
PL (1) | PL3105213T3 (pt) |
PT (1) | PT3105213T (pt) |
RS (1) | RS58498B1 (pt) |
SG (1) | SG11201605654QA (pt) |
SI (1) | SI3105213T1 (pt) |
TR (1) | TR201903892T4 (pt) |
TW (1) | TWI669297B (pt) |
UA (1) | UA118280C2 (pt) |
UY (1) | UY35994A (pt) |
WO (1) | WO2015122187A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2905606C (en) | 2013-03-13 | 2021-03-09 | Astellas Pharma Inc. | Guanidino benzoic acid esters useful in treating renal disorders |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
CR20200362A (es) | 2014-02-13 | 2020-10-26 | Incyte Corp | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
HUE046273T2 (hu) | 2014-02-13 | 2020-02-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
WO2016158788A1 (ja) * | 2015-03-27 | 2016-10-06 | 武田薬品工業株式会社 | 縮合複素環化合物 |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Lsd1阻害剤の塩 |
BR112020008676A2 (pt) * | 2017-11-02 | 2020-10-27 | Ube Industries, Ltd. | composto, e, composição farmacêutica. |
JP7199774B2 (ja) | 2018-05-09 | 2023-01-06 | エルジー・ケム・リミテッド | エンテロペプチダーゼ阻害活性を示す新規化合物 |
AR116019A1 (es) | 2018-08-27 | 2021-03-25 | Scohia Pharma Inc | Derivados de guanidinobenzoilo como inhibidores de enteropeptidasa |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
US20220281866A1 (en) | 2019-07-19 | 2022-09-08 | Janssen Pharmaceutica Nv | 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase |
JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
WO2021166899A1 (ja) * | 2020-02-17 | 2021-08-26 | 宇部興産株式会社 | インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤 |
CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
CN111803652B (zh) * | 2020-08-04 | 2021-09-14 | 南通康是美生物科技有限公司 | 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
WO1994013631A1 (en) | 1992-12-10 | 1994-06-23 | Teikoku Chemical Industries Co., Ltd. | Propionic acid derivative |
JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
JPH09124571A (ja) | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
EP0893437A4 (en) | 1996-04-10 | 2000-12-27 | Ono Pharmaceutical Co | GUANIDINO TRYPTASE INHIBITOR |
JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターd阻害剤 |
JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規4h−3,1−ベンゾオキサジン−4−オン誘導体 |
JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | Sulphonic derivatives, process for their preparation and their use |
ZA200503967B (en) | 2002-11-01 | 2006-11-29 | Takeda Pharmaceutical | Agent for preventing or treating neuropathy |
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
EP1815865A4 (en) | 2004-11-08 | 2010-08-25 | Ono Pharmaceutical Co | THERAPEUTIC AGENT AGAINST DIABETES WITH A PROTEASE-INHIBITING COMPOUND |
CA2588087A1 (en) | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
EP1811865B1 (en) | 2004-11-26 | 2008-07-16 | N.V. Nutricia | Infant nutrition with protease inhibitor |
JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
JP2006348023A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミン誘導体を有効成分として含む血管新生阻害剤 |
US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
US20080009530A1 (en) | 2005-08-10 | 2008-01-10 | Hidenori Abe | Therapeutic Agent for Diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
AU2007208495A1 (en) * | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
AR061644A1 (es) | 2006-06-27 | 2008-09-10 | Takeda Pharmaceutical | Derivados de benzofurano |
EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
MX2009003972A (es) | 2006-10-19 | 2009-04-27 | Takeda Pharmaceutical | Compuesto de indol. |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
JP2010517935A (ja) | 2007-02-09 | 2010-05-27 | 武田薬品工業株式会社 | Ppar−ガンマのパーシャルアゴニストとしての縮合環化合物 |
JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
HUE028064T2 (en) | 2007-12-03 | 2016-11-28 | Obe Therapy Biotechnology | Inhibitors of enteropeptidase boropeptide and their use in the treatment of diseases associated with obesity, overweight and / or abnormal fat metabolism |
WO2011071048A1 (ja) | 2009-12-07 | 2011-06-16 | 味の素株式会社 | ヘテロアリールカルボン酸エステル誘導体 |
WO2012169579A1 (ja) | 2011-06-07 | 2012-12-13 | 味の素株式会社 | ヘテロ環カルボン酸エステル誘導体 |
WO2013039187A1 (ja) | 2011-09-15 | 2013-03-21 | アステラス製薬株式会社 | グアニジノ安息香酸化合物 |
WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
CN104902921A (zh) | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
MX2015011618A (es) | 2013-03-08 | 2015-12-17 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. |
CA2905606C (en) * | 2013-03-13 | 2021-03-09 | Astellas Pharma Inc. | Guanidino benzoic acid esters useful in treating renal disorders |
PE20160208A1 (es) | 2013-06-21 | 2016-05-04 | Myokardia Inc | Compuestos de pirimidinodiona contra estados cardiacos |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
HUE046273T2 (hu) | 2014-02-13 | 2020-02-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
CR20200362A (es) | 2014-02-13 | 2020-10-26 | Incyte Corp | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) |
-
2015
- 2015-02-11 US US14/619,489 patent/US9346776B2/en active Active
- 2015-02-12 MY MYPI2016702925A patent/MY173607A/en unknown
- 2015-02-12 AR ARP150100411A patent/AR099400A1/es active IP Right Grant
- 2015-02-12 JP JP2016550664A patent/JP6383427B2/ja active Active
- 2015-02-12 SI SI201530626T patent/SI3105213T1/sl unknown
- 2015-02-12 KR KR1020167025277A patent/KR102378454B1/ko active IP Right Grant
- 2015-02-12 WO PCT/JP2015/000639 patent/WO2015122187A1/en active Application Filing
- 2015-02-12 US US15/117,538 patent/US9969705B2/en active Active
- 2015-02-12 CR CR20160367A patent/CR20160367A/es unknown
- 2015-02-12 BR BR112016018455-6A patent/BR112016018455B1/pt active IP Right Grant
- 2015-02-12 PE PE2016001239A patent/PE20161243A1/es unknown
- 2015-02-12 RS RS20190324A patent/RS58498B1/sr unknown
- 2015-02-12 JO JOP/2015/0028A patent/JO3472B1/ar active
- 2015-02-12 CN CN201580007800.9A patent/CN105980370B/zh active Active
- 2015-02-12 EA EA201691619A patent/EA032201B1/ru not_active IP Right Cessation
- 2015-02-12 HU HUE15706546A patent/HUE042709T2/hu unknown
- 2015-02-12 DK DK15706546.7T patent/DK3105213T3/en active
- 2015-02-12 PL PL15706546T patent/PL3105213T3/pl unknown
- 2015-02-12 TR TR2019/03892T patent/TR201903892T4/tr unknown
- 2015-02-12 PT PT15706546T patent/PT3105213T/pt unknown
- 2015-02-12 EP EP15706546.7A patent/EP3105213B1/en active Active
- 2015-02-12 NZ NZ722035A patent/NZ722035A/en unknown
- 2015-02-12 AU AU2015216438A patent/AU2015216438B2/en active Active
- 2015-02-12 TW TW104104693A patent/TWI669297B/zh active
- 2015-02-12 MA MA39246A patent/MA39246A1/fr unknown
- 2015-02-12 ME MEP-2019-89A patent/ME03422B/me unknown
- 2015-02-12 UY UY0001035994A patent/UY35994A/es not_active Application Discontinuation
- 2015-02-12 CA CA2938191A patent/CA2938191C/en active Active
- 2015-02-12 ES ES15706546T patent/ES2717113T3/es active Active
- 2015-02-12 MX MX2016010559A patent/MX368392B/es active IP Right Grant
- 2015-02-12 LT LTEP15706546.7T patent/LT3105213T/lt unknown
- 2015-02-12 SG SG11201605654QA patent/SG11201605654QA/en unknown
- 2015-12-02 UA UAA201609351A patent/UA118280C2/uk unknown
-
2016
- 2016-07-19 IL IL246838A patent/IL246838B/en active IP Right Grant
- 2016-07-28 CL CL2016001911A patent/CL2016001911A1/es unknown
- 2016-08-10 PH PH12016501582A patent/PH12016501582A1/en unknown
- 2016-08-11 DO DO2016000206A patent/DOP2016000206A/es unknown
- 2016-08-11 EC ECIEPI201667137A patent/ECSP16067137A/es unknown
-
2018
- 2018-08-03 JP JP2018146459A patent/JP6529649B2/ja active Active
-
2019
- 2019-02-26 HR HRP20190369TT patent/HRP20190369T1/hr unknown
- 2019-03-27 CY CY20191100356T patent/CY1121534T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016018455A2 (pt) | composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto. | |
CL2016001080A1 (es) | Benzamidas sustituidas para tratamiento de artrópodos. | |
BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
BR112017019269A2 (pt) | mecanismos de acionamento para bombas de distribuição de drogas. | |
DK3174868T3 (da) | Forbindelser, der er aktive mod bromodomæner | |
DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
CL2014003039S1 (es) | Carcasa para autoinyector. | |
BR112016018548A2 (pt) | composto, ácido, medicamento, e, uso de um composto. | |
CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
DK3332767T3 (da) | Flydende inhalationsformulering, der omfatter RPL554 | |
BR112015021003A2 (pt) | composições e métodos para a produção biológica de isopreno. | |
DK3155017T3 (da) | Forbedrede lægemidler til insulinresistens | |
BR112017002318A2 (pt) | combinações de fármacos para tratar mieloma múltiplo. | |
EP2985005A4 (en) | Animal syringe having improved structure | |
CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
BR112016017464A2 (pt) | uso de ácido guanidinoacético e/ ou creatina para aumentar a taxa de eclosão de ovos. | |
EP3135293A4 (en) | Agent for preventing or ameliorating diabetes | |
BR112016026143A2 (pt) | os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico. | |
FR3023171B1 (fr) | Autoinjecteur. | |
EP3192792A4 (en) | Aminosulfonyl compound, preparation method therefor and use thereof | |
EP3150508A4 (en) | Pump stopper | |
BR112016014688A2 (pt) | composição aquosa, processo para a preparação de uma composição aquosa e uso de um sal de um ácido orgânico | |
FR3023170B1 (fr) | Autoinjecteur. | |
DK3258920T3 (da) | Fast farmaceutisk doseringsform, der er egnet til anvendelse som drikkevandsmedikament | |
ZA201701714B (en) | Anthostema senegalense-based composition, for use as an anti-aids drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: SCOHIA PHARMA, INC. (JP) |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2015, OBSERVADAS AS CONDICOES LEGAIS |